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Background
Inter-subtype neutralization of HIV-1 and cross-neutrali-
zation between HIV 1 and 2 was explored using plasma
collected from 54 HIV-infected individuals within the
framework of a case control study in Guinea-Bissau, West
Africa. Twenty one were infected with HIV-1, 21 with HIV-
2 and 12 were dually HIV-1/2 seropositive, of whom 5
were from a professional cohort in the same area. HTLV-I
status was also known, five HIV-1-infected and 10 HIV-2-
infected were HTLV-I seropositive.
Methods
The plasma were tested for neutralizing activity against
five HIV-1 and one HIV-2 isolates. Two HIV-1 (subtype A/
G) isolates and the HIV-2 isolate were from Guinea-Bis-
sau, one HIV-1 subtype B isolate was from Sweden and
two subtype C isolates were from Brazil and India, respec-
tively. Plaque reduction assay on U87.CD4-CCR5 cells
was used and neutralization was scored as negative (<30%
neutralization), moderate (30–59% neutralization) and
strong (≥60% neutralization).
Results
Sixty seven percent of HIV-1 plasma strongly neutralized
at least one HIV-1 isolate, while 33% strongly neutralized
at least two HIV-1 isolates. All HIV-2 plasma neutralized
the HIV-2 isolate (70% strongly) and 29% strongly neu-
tralized at least one HIV-1 isolate (5% neutralized at least
two HIV-1 isolates). This is to be compared with 10% of
HIV-1 plasma that neutralized the HIV-2 isolate.
Conclusion
HTLV-I co-infection appears to modulate neutralization
in HIV-1 infection, whereas gender seems to influence
neutralization by HIV-2 plasma.
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